• For preexposure prophylaxis, RABAVERT is contraindicated for persons who have had a history of anaphylaxis to RABAVERT, or to any component of RABAVERT, including egg or chicken proteins, bovine gelatin, neomycin, chlortetracycline, and amphotericin B
    See full Important Safety Information below
Telephone Receiver Handset

Any Questions?

Contact the Vaccines
Support Center

Learn More

Diagnosis Codes

ICD-10-CM codes are used to report diseases and conditions. These will be needed on the CMS-1500 form.

View More Information

Printable Summary Sheet

This PDF provides a summary of CPT codes for GSK Vaccines.

View Summary Sheet
View all Vaccines
Coding for RABAVERT
Print Page

This section provides the vaccine product codes as well as some common administration codes associated with immunization using RABAVERT. Administration codes will vary based on the service provided. Please refer to your most up-to-date Current Procedural Terminology (CPT) and International Classification of Diseases (ICD) manuals for appropriate coding.


RABAVERT is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

Description [23] NDCs* ICD-10-CM
Code [8]**
The adult, child, and infant dosage:
1.0 mL

Preexposure vaccination consists of three doses of RABAVERT 1.0 mL, intramuscularly, one each on days 0, 7, and 21 or 28
90675 RABAVERT is supplied as a 1.0 mL single-dose kit NDC 58160-964-12 Z23
Package contents:
1 vial of freeze-dried vaccine containing a single dose: NDC 58160-966-01
1 disposable prefilled syringe of Sterile Diluent for reconstitution (1 mL): NDC 58160-967-02
1 small needle for injection (25 gauge, 1 inch) and 1 long needle for reconstitution (21 gauge, 1 ½ inch):  
Booster immunization dose is 1 mL, given intramuscularly

Postexposure dosage for previously unvaccinated persons consists of a total of 5 injections of 1 mL each on days 0, 3, 7, 14, and 28 in conjunction with HRIG on day 0

Postexposure dosage for previously immunized persons consists of two IM injections of 1 mL each on day 0 and 3
* Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC. For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11. [14]
** With the implementation of ICD-10-CM, all vaccine-related encounters are reported as code Z23 for all vaccines given.
TIP To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.
Immunization Administration Codes (CPT) [6]
CPT Description
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)
+90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
Adapted from American Medical Association. Procedural Coding Expert:
The Ultimate Guide to CPT Coding 2014
TIP If reporting multiple vaccine administrations given to a patient through age 18 years on the same date along with counseling by a qualified healthcare professional, report one administration code (90460) for each vaccine administered.


RABAVERT is a registered trademark of the GSK group of companies.

RABWCNT180001 February 2019

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit to file a report, or call 1-800-822-7967.

To learn more about the
GSK Vaccines Access Program,
click here.
Contact Us